Search results
Results From The WOW.Com Content Network
Adermatoglyphia is an extremely rare genetic disorder that prevents the development of fingerprints. Five extended families worldwide are known to be affected by this condition. Five extended families worldwide are known to be affected by this condition.
adermatoglyphia with neo-natal blisters and facial milia: Complications: Usually none (health-wise), however; hypohidrosis may lead to heat exhaustion or even a heat stroke, and the absence of fingerprints may complicate the use of systems that require fingerprint-identification: Usual onset: Birth: Duration: Life-long: Types: Adermatoglyphia ...
Osteoporosis, including drug- and cancer-related osteoporosis, giant cell tumour of bone and hypercalcaemia of malignancies: Hypercholesterolaemia, cataract, urinary retention, hypocalcaemia, osteonecrosis of the jaw and anaphylaxis. Gemtuzumab ozogamicin: IV: CD33 antibody that induces apoptosis of the tagged cell. Acute myeloid leukaemia
When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies. Types of monoclonal antibodies with other structures than naturally occurring antibodies.
This is a list of drugs and substances that are known or suspected to cause Stevens–Johnson syndrome This is a dynamic list and may never be able to satisfy particular standards for completeness. You can help by adding missing items with reliable sources .
In January 2013, Edimer Pharmaceuticals, a biotechnology company based in Cambridge, MA, USA, initiated a Phase I, open-label, safety and pharmacokinetic clinical study of EDI200, a drug aimed at the treatment of XLHED. During development in mice and dogs EDI200 has been shown to substitute for the altered or missing protein resulting from the ...
Dermatoglyphics, when correlated with genetic abnormalities, aids in the diagnosis of congenital malformations at birth or soon after.. Klinefelter syndrome: excess of arches on digit 1, more frequent ulnar loops on digit 2, overall fewer whorls, lower ridge counts for loops and whorls as compared with controls, and significant reduction of the total finger ridge count.
Clinical studies have shown that the most common side effect is a slight reaction at the site of injection in the form of redness, and sometimes swelling. [4] Clinical studies have shown that, one hour after injection, the incidence of at least one moderate or severe local skin reaction per treatment cycle was 12% in 4 patients treated with ganirelix and 25% in patients treated subcutaneously ...